Skip to main content


Fig. 2 | BMC Cancer

Fig. 2

From: SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

Fig. 2

SoLAT was more efficiently induced cell cycle arrest and reduced anti-apoptotic factor than each treated groups on GSP2 and GSP3. a and d Anti-cancer activity of SoLAT on the advanced PTC cell line. Sorafenib Lenvatinib alternating treatment SoLAT was more efficient than the individual treatments. b and e Immunofluorescence staining for Ki-67. The SoLAT group suppressed Ki-67 expression. c and f Immunoblot analysis of cell-cycle arrest and apoptotic proteins showed marked increase in the levels of p21, p53, Apaf-1, and cleaved caspase 3, and decrease in the levels of Ki-67, cyclin D1, CDK 4, p-NFkB, and Bcl-2 in the SoLAT group than in the individual sorafenib or lenvatinib treatment groups

Back to article page